tiprankstipranks
Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
Hong Kong Market
2696
Shanghai Henlius Biotech, Inc. Class H
RESEARCH TOOLSreports

Shanghai Henlius Biotech, Inc. Class H (2696) Stock News & Sentiment

7 Followers
Henlius Wins NMPA Nod to Start Trials of Cetuximab Biosimilar HLX05-N
Premium
Company Announcements
Henlius Wins NMPA Nod to Start Trials of Cetuximab Biosimilar HLX05-N
2h ago
2696
Henlius Starts Phase 1 Trial of HLX319, a Subcutaneous Pertuzumab-Trastuzumab Biosimilar in China
Premium
Company Announcements
Henlius Starts Phase 1 Trial of HLX319, a Subcutaneous Pertuzumab-Trastuzumab Biosimilar in China
4d ago
2696
Henlius Wins China Nod to Expand Indications for Rituximab Biosimilar HANLIKANG
Premium
Company Announcements
Henlius Wins China Nod to Expand Indications for Rituximab Biosimilar HANLIKANG
5d ago
2696
Henlius Wins NMPA Nod to Begin Trials of HER2 Breast Cancer Biosimilar HLX319
Premium
Company Announcements
Henlius Wins NMPA Nod to Begin Trials of HER2 Breast Cancer Biosimilar HLX319
13d ago
2696
Henlius Wins NMPA Nod to Start Trials of Novel Hyaluronidase Injection
Premium
Company Announcements
Henlius Wins NMPA Nod to Start Trials of Novel Hyaluronidase Injection
14d ago
2696
Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe
Premium
Company Announcements
Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe
15d ago
2696
Henlius Starts Phase 1b/2 Trial of CD47-Targeting HLX701 in Advanced Colorectal Cancer
Premium
Company Announcements
Henlius Starts Phase 1b/2 Trial of CD47-Targeting HLX701 in Advanced Colorectal Cancer
19d ago
2696
More HK:2696 News >

2696 News on the Web

Henlius Starts Phase 1 Trial of HLX319, a Subcutaneous Pertuzumab-Trastuzumab Biosimilar in China
TipRanks News
Bullish
Citic Securities Reaffirms Their Buy Rating on Shanghai Henlius Biotech, Inc. Class H (2696)
TipRanks News
Bullish
Henlius Wins China Nod to Expand Indications for Rituximab Biosimilar HANLIKANG
TipRanks News
Bullish
Henlius Wins NMPA Nod to Begin Trials of HER2 Breast Cancer Biosimilar HLX319
TipRanks News
Bullish
Henlius Wins NMPA Nod to Start Trials of Novel Hyaluronidase Injection
TipRanks News
Bullish
Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe
TipRanks News
Bullish
SWS Res Sticks to Their Buy Rating for Shanghai Henlius Biotech, Inc. Class H (2696)
TipRanks News
Bullish
Shenwan Hongyuan Sticks to Their Buy Rating for Shanghai Henlius Biotech, Inc. Class H (2696)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
HK:2696
Sector Average
Media Buzz
This Week3 articles
Weekly Average4 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is HK:2696’s Media Buzz Sentiment?
3 articles about HK:2696 were published this week. In an average week, 4 articles are published.
    What is HK:2696’s weekly average amount of articles?
    In an average week, 4 articles about HK:2696 are published.
      What is HK:2696’s News Sentiment?
      100% of articles about HK:2696 were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        TXTMProText Mobility
        STAAStaar Surgical
        ALLOAllogene Therapeutics
        REPLReplimune Group
        IVVDInvivyd
        Showing the stocks with the most bullish news sentiment over the past week